Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Dutch biotechnology company Crucell said that Merck & Co. has exercised an option for the exclusive use of Crucell's PER.C6 technology and an option for access to Crucell's AdVac vaccine technology in two infectious disease areas.
Subscribe to our email newsletter
Dr Jaap Goudsmit, Crucell's chief scientific officer, said: “Crucell's vaccine technologies, PER.C6 and AdVac, are increasingly used by the vaccine industry to develop important novel vaccines for infectious diseases. This agreement further broadens the number of disease areas in which our technologies are used.”
Under the terms of the agreement, Crucell acquires rights to certain cell-line technology developed by Merck for the manufacturing of recombinant proteins. The option and the related rights to certain technology developed by Merck originate from the cross-license agreement executed in December 2006 between Crucell and Merck. Specifics concerning the infectious disease indications remain undisclosed.